Silvia Antolín Novoa

5PUBLICATIONS
16CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 30, 2023
Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).

Francisco Ayala de la Peña, Silvia Antolín Novoa, Joaquín Gavilá Gregori

|Aug 20, 2023
Foot health and quality of life in women with breast cancer undergoing chemotherapy: a cross-sectional study.

Raquel Veiga-Seijo, Sonia Pertega-Diaz, Maria Eva Perez-Lopez

|Jun 16, 2023
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).

Francisco Ayala de la Peña, Silvia Antolín Novoa, Joaquín Gavilá Gregori

|Jun 12, 2021
Correction to: Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2‑positive breast cancer?

Silvia Antolín, Lucía García-Caballero, Cristina Reboredo

|May 02, 2021
Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?

Silvia Antolín, Lucía García-Caballero, Cristina Reboredo

Pageof 1